Trial Profile
Phase III trial of NLX P101 in patients with Parkinson's disease.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 20 Aug 2022
Price :
$35
*
At a glance
- Drugs NLX P101 (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Neurologix
- 11 Aug 2022 According to a MeiraGTx media release, company expects to initiate enrollment in this study during the second half of 2022 with material manufactured in its cGMP facility in London, United Kingdom.
- 16 Mar 2011 Trial is still being planned.
- 07 May 2008 New trial record.